Book chapters

Elsevier,

Clinical Immunology (Sixth Edition)
Principles and Practice
2023, Pages 832-842

This content links with Goal 3: Good health and well-being and Goal 10: Reduced Inequalities by advancing understanding of MG pathophysiology to improve current therapies and contribute to the development of novel, MG-specific therapeutics.
Elsevier,

Clinical Immunology (Sixth Edition)
Principles and Practice
2023, Pages 573-585

This content links with Goal 3: Good health and well-being and Goal 10: Reduced Inequalities by focusing on the role of eosinophils in health and disease, including novel therapeutic approaches and their contribution to our understanding of the role that eosinophils play in homeostasis and pathogenesis.
Elsevier,

Viral, Parasitic, Bacterial, and Fungal Infections: Antimicrobial, Host Defense, and Therapeutic Strategies, 2023, Pages 757-770

This content aligns with Goal 3: Good Health. As per World Health Organization (WHO) recommendations, it is required to implement the evaluation studies of ethnomedicines for HIV/AIDS, malaria, tuberculosis, and other infectious treatments, to find effective and economical therapeutic agents.
Elsevier,

Health Care Today in the United States

2023, Pages 47-67

The rights of all citizens are designed to be protected by laws. It is important that all health care professionals understand the relationships that they have with their patients, under the law. This chapter supports WHO SDG3.
Elsevier,

Clinical Immunology (Sixth Edition)
Principles and Practice
2023, Pages 525-541

This content aligns with Goal 3: Good Health and Wellbeing by highlighting the interactions of the Human immunodeficiency virus (HIV)-1 with the immune system.
Elsevier,

Clinical Immunology (Sixth Edition): Principles and Practice, 2023, Pages 972-982

This content aligns with Goal 3: Good Health, this chapter aims at elucidating the main characteristics of AIH, PBC, and PSC, with particular interest for the clinical manifestations, pathogenesis, autoantibodies, and therapeutic options.
Elsevier,

Oncogenic Viruses, Volume 2: Medical Applications of Viral Oncology Research, 2023, Pages 173-189

This content aligns with Goal 3: Good Health. Hepatitis B remains a worrying health problem for several countries. Although vaccination has clearly been shown to be very effective in the prevention and control of the disease globally, the emergence of mutant resistant liver infections is of concern. Thus the development of new common vaccines for the prevention of all types of hepatitis is warranted.
Elsevier,

Oncogenic Viruses

Volume 2: Medical Applications of Viral Oncology Research

2023, Pages 253-266

Oncovirus cancer is a group of more than 100 different diseases. It can develop almost anywhere in the body. Initiation of cancer largely due to genetic changes interferes with the normal process, leading to uncontrolled cell growth. This huge cell mass transforms into a tumor, which can be benign or cancerous and can be malignant, which can grow and spread to other parts of the body. Whereas some types of cancers are nontumorous like leukemia, cancers like lymphoma and myeloma are tumorous. Apart from genetic mutations and other environmental factors such as chemical changes and change in lifestyle, approximately 12% of human cancers occur due to viruses and they are known as oncoviruses. A huge group of people harbors at least one of these oncoviruses, but few go on to develop into cancer. The path from oncovirus infection to the onset of cancer in humans involves a complex process. The viral factors and host interaction create a favorable microenvironment for oncogenesis. At present, seven human oncoviruses are known: Epstein–Barr virus (EBV), human papillomavirus (HPV), Hepatitis B and C viruses (HBV and HCV), human T-cell lymphotropic virus-1 (HTLV-1), human herpesvirus-8 (HHV-8), and Merkel cell polyomavirus (MCPyV). As the first human oncovirus, EBV was first detected in Burkitt lymphoma cells by electron microscopy in 1964. Since then work in oncovirology has been carried out on a large scale to understand the host–virus pathogenesis. Globally, around 20% of all cancers are caused by infectious agents and 12% are caused due to the oncoviruses, and of these, approximately 80% of viral cancers occur in the developing nations. With the help of the existing biochemical techniques such as genomics and proteomics, the identification of virus and their role in the cancer pathogenesis could be investigated, but still knowledge about their microenvironment and interactions is lacking. Current computational techniques support the deep mining of information, and knowledge modeling with preexisting data helps in understanding the sequence-to-sequence mapping followed by structure elucidation, which brings more curated data into the picture. Bioinformatics, cheminformatics, and amalgamation of artificial intelligence play an important role in research in the field of oncovirology. The large datasets obtained from multiple biochemical experiments contain gigabytes of data related to the sequence, structure, and interactions of oncoviruses. Techniques such as computational genomics, computational proteomics, interactomics, sequence analysis, structure modeling, systems biology, protein modeling, and computer-aided drug design have significantly contributed to making research in this field cost-effective.
Elsevier,

Intelligent Environments: Advanced Systems for a Healthy Planet, Second Edition, 2023, pp 475-497

This chapter advances the UN SDG goals 9 and 11 by discussing the growing field of Digital City Science and the convergence of digital cities and sustainable urban development.
Elsevier,

Outbreaks, Epidemics, and Health Security

COVID-19 and Ensuring Future Pandemic Preparedness in Ireland and the World

2023, Pages 3-17

Future global health crises should, wherever possible, be managed in a bipartisan way, mindful of the divides they create, supporting SDG3.

Pages